Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.34 |
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321603 | 1.00 | KDM4E (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL5967472 | 0.86 | ACE (0.45) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL5967479 | 0.86 | ACE (0.45) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL5712807 | 0.85 | TGFBR1 (0.42) | LMNAOR51E2TGFBR1MMECA1 | |
| SCHEMBL5712806 | 0.85 | TGFBR1 (0.42) | LMNAOR51E2TGFBR1MMECA1 | |
| SCHEMBL2633849 | 0.85 | ACE (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL8974998 | 0.85 | ACE (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL9924203 | 0.82 | KDM4E (0.47) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL11095681 | 0.82 | KDM4E (0.42) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4263217 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941219-A1 | SAPONIN-BASED VACCINE ADJUVANTS | The UAB Research Foundation (US) | 2022-01-26 | — | — | EP | claimed |
| WO-2020190959-A1 | SAPONIN-BASED VACCINE ADJUVANTS | THE UAB RESEARCH FOUNDATION (US) | 2020-09-24 | — | — | WO | claimed |
| EP-3377099-A1 | ADJUVANTING SYSTEMS AND WATER-FREE VACCINE COMPOSITIONS COMPRISING A POLYI:C POLYNUCLEOTIDE ADJUVANT AND A LIPID-BASED ADJUVANT | ImmunoVaccine Technologies Inc. (CA) | 2018-09-26 | — | — | EP | claimed |
| CN-108430505-A | The auxiliary system of adjuvant including polyinosinic acid polynucleotides adjuvant and based on lipid and anhydrous vaccine composition | 免疫疫苗技术有限公司 | 2018-08-21 | — | — | CN | claimed |
| EP-3174554-A1 | NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF | Boehringer Ingelheim Vetmedica GmbH (DE) | 2017-06-07 | — | — | EP | claimed |
| WO-2016016401-A1 | NANOPARTICLES, METHODS OF PREPARATION, AND USES THEREOF | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2016-02-04 | — | — | WO | claimed |
| US-20100003275-A1 | Immunostimulatory Composition comprising Lipoprotein in Microalgae Extract | THE UNIVERSITY OF MISSISSIPPI (US) | 2010-01-07 | — | — | US | claimed |
| EP-2064232-A2 | IMMUNOSTIMULATORY COMPOSITION COMPRISING LIPOPROTEIN IN MICROALGAE EXTRACT | University of Mississippi (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2009023714-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF HYPERTENSION | THYMON, LLC (US) | 2009-02-19 | — | — | WO | claimed |
| WO-2008031092-A9 | IMMUNOSTIMULATORY COMPOSITION COMPRISING LIPOPROTEIN IN MICROALGAE EXTRACT | UNIV MISSISSIPPI (US) | 2008-07-31 | — | — | WO | claimed |
| WO-2008031092-A2 | IMMUNOSTIMULATORY COMPOSITION COMPRISING LIPOPROTEIN IN MICROALGAE EXTRACT | UNIVERSITY OF MISSISSIPPI (US) | 2008-03-13 | — | — | WO | claimed |
| CN-1326567-C | Egg yolk antibody composition for preventing and treating atypical pneumonia and its preparation method | GUO ZHANJUN (CN) | 2007-07-18 | — | — | CN | claimed |
| US-20050192217-A1 | Utilization of lipopeptides or lipoproteins in wound treatment and infection prophylaxis | MUHLRADT PETER (DE) | 2005-09-01 | — | — | US | claimed |
| CN-1559610-A | Vaccine curing for disease and its preparation method | 郭占军 | 2005-01-05 | — | — | CN | claimed |
| CN-1557487-A | Immunogenicity composition for preventing and treating diseases and its preparation | 郭占军 | 2004-12-29 | — | — | CN | claimed |
| CN-1478550-A | Egg yolk antibody composition for preventing and treating atypical pneumonia and its preparation method | 郭占军 | 2004-03-03 | — | — | CN | claimed |
| CN-1460522-A | Egg yolk antibody composite for preventing and curing diseases and its preparaion method | GUO ZHANJUN (CN) | 2003-12-10 | — | — | CN | claimed |
| EP-1077717-B1 | USE OF LIPOPEPTIDES OR LIPOPROTEINS FOR WOUND TREATMENT | BIOTECHNOLOG FORSCHUNG GMBH (DE) | 2003-07-23 | — | — | EP | claimed |
| WO-1995000846-A1 | DOMAIN LIGATION STRATEGY TO ENGINEER PROTEINS WITH UNUSUAL ARCHITECTURES | TAM JAMES P (US) | 1995-01-05 | — | — | WO | claimed |
| EP-3728289-B1 | OPTIMISED COMPOUNDS | Axelia Oncology Pty Ltd (AU) | 2025-09-10 | — | — | EP | disclosed |
| US-20250066416-A1 | OPTIMISED COMPOUNDS | THE UNIVERSITY OF MELBOURNE (AU) | 2025-02-27 | — | — | US | disclosed |
| EP-3527224-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-02-26 | — | — | EP | disclosed |
| EP-4144368-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2025-02-26 | — | — | EP | disclosed |
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2025-02-06 | — | — | US | disclosed |
| US-12195557-B2 | Optimised compounds | Axelia Oncology Pty Ltd (AU) | 2025-01-14 | — | — | US | disclosed |
| US-12139512-B2 | Pre-fusion RSV F antigens | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-11-12 | — | — | US | disclosed |
| US-20240299527-A1 | RSV IMMUNIZATION REGIMEN | NOVARTIS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| EP-4183412-B1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-08-14 | — | — | EP | disclosed |
| US-20240239845-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2024-07-18 | — | — | US | disclosed |
| US-20240034773-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-02-01 | — | — | US | disclosed |
| WO-2023232807-A1 | IMMUNOGENIC COMPOSITION | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-07 | — | — | WO | disclosed |
| US-11827694-B2 | RSV F protein compositions and methods for making same | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-28 | — | — | US | disclosed |
| US-11820812-B2 | RSV F protein compositions and methods for making same | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11813323-B2 | RSV immunization regimen | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-14 | — | — | US | disclosed |
| US-20230357369-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357370-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357371-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230348574-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348575-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-11-02 | — | — | US | disclosed |
| US-20230303669-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-09-28 | — | — | US | disclosed |
| US-20230287056-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2023-09-14 | — | — | US | disclosed |
| WO-2023156409-A1 | METHODS OF TREATING BLOOD DISORDERS WITH VWF-TARGETED MONOSPECIFIC ANTIBODIES | HEMAB APS (DK) | 2023-08-24 | — | — | WO | disclosed |
| EP-4218799-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GlaxoSmithKline Biologicals S.A. (BE) | 2023-08-02 | — | — | EP | disclosed |
| EP-4216992-A1 | PARTICLE COMPRISING AN RSV-F PROTEIN FOR USE IN RSV VACCINATION | DBV Technologies (FR) | 2023-08-02 | — | — | EP | disclosed |
| EP-4218800-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GlaxoSmithKline Biologicals S.A. (BE) | 2023-08-02 | — | — | EP | disclosed |
| EP-4183412-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GlaxoSmithKline Biologicals S.A. (BE) | 2023-05-24 | — | — | EP | disclosed |
| US-11655284-B2 | RSV F protein compositions and methods for making same | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-05-23 | — | — | US | disclosed |
| US-11629181-B2 | RSV F protein compositions and methods for making same | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-04-18 | — | — | US | disclosed |
| EP-4159232-A1 | RSV IMMUNIZATION REGIMEN | GlaxoSmithKline Biologicals S.A. (BE) | 2023-04-05 | — | — | EP | disclosed |
| US-20230072995-A1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-03-09 | — | — | US | disclosed |
| EP-4144368-A1 | RSV IMMUNIZATION REGIMEN | GlaxoSmithKline Biologicals S.A. (BE) | 2023-03-08 | — | — | EP | disclosed |
| US-20220372115-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-11-24 | — | — | US | disclosed |
| US-20220340645-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-10-27 | — | — | US | disclosed |
| US-20220332766-A1 | PRE-FUSION RSV F ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-10-20 | — | — | US | disclosed |
| US-20220332767-A1 | PRE-FUSION RSV F ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-10-20 | — | — | US | disclosed |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-11452773-B2 | RSV immunization regimen | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-09-27 | — | — | US | disclosed |
| EP-4025204-A1 | CANCER IMMUNOTHERAPY | Axelia Oncology Pty Ltd (AU) | 2022-07-13 | — | — | EP | disclosed |
| US-20220213177-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-07-07 | — | — | US | disclosed |
| WO-2022103927-A1 | IMMUNOGENIC COMPOSITIONS FOR CORONAVIRUSES | SHAPE BIOPHARMACEUTICALS INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3988115-A2 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GlaxoSmithKline Biologicals S.A. (BE) | 2022-04-27 | — | — | EP | disclosed |
| EP-3178490-B1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-04-20 | — | — | EP | disclosed |
| US-11261239-B2 | RSV F protein compositions and method for making same | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2022-03-01 | — | — | US | disclosed |
| US-20210230217-A1 | OPTIMISED COMPOUNDS | Axelia Oncology Pty Ltd (AU) | 2021-07-29 | — | — | US | disclosed |
| WO-2021107775-A1 | TEIPP PEPTIDE VARIANT AND USES THEREOF | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021042171-A1 | CANCER IMMUNOTHERAPY | Ena Therapeutics Pty Ltd (AU) | 2021-03-11 | — | — | WO | disclosed |
| EP-3728289-A1 | OPTIMISED COMPOUNDS | Ena Therapeutics Pty Ltd (AU) | 2020-10-28 | — | — | EP | disclosed |
| CN-111491943-A | Optimized compounds | 艾娜医疗私人有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20200172600-A1 | RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2020-06-04 | — | — | US | disclosed |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20200113963-A1 | Aloe Preparation For Skin Enhancement | WOODCLIFF SKINCARE SOLUTIONS, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| EP-3611269-A1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | GlaxoSmithKline Biologicals SA (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-10543247-B2 | Aloe preparation for skin enhancement | WOODCLIFF SKINCARE SOLUTIONS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10485761-B2 | Irradiated biodegradable polymer microparticles | GLAXOSMITHKLINE BIOLOGICALS, S.A. (BE) | 2019-11-26 | — | — | US | disclosed |
| CN-110461351-A | Treatment of respiratory infections with TLR2 agonists | Ena Therapeutics Pty Ltd | 2019-11-15 | — | — | CN | disclosed |
| CN-105477640-B | Novel immunostimulatory method | 因纳瓦克私人有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110234401-A | METHODS AND COMPOSITIONS FOR ADAPTIVE IMMUNE MODULATION | 德克萨斯大学系统董事会 | 2019-09-13 | — | — | CN | disclosed |
| US-20190275141-A1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2019-09-12 | — | — | US | disclosed |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3527224-A1 | RSV IMMUNIZATION REGIMEN | GlaxoSmithKline Biologicals S.A. (BE) | 2019-08-21 | — | — | EP | disclosed |
| US-10342862-B2 | RSV immunization regimen | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2019-07-09 | — | — | US | disclosed |
| CN-109963585-A | Fusions for treating cancer comprising cell penetrating peptides, polyepitopes and TLR peptide agonists | 阿尔勒治疗公司 | 2019-07-02 | — | — | CN | disclosed |
| US-10301396-B2 | Reduction of endotoxin in polysialic acids | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2019-05-28 | — | — | US | disclosed |
| US-10287324-B2 | Norovirus derived immunogenic compositions and methods | NOVARTIS AG (CH) | 2019-05-14 | — | — | US | disclosed |
| EP-2591117-B1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-05-08 | — | — | EP | disclosed |
| EP-3463444-A1 | IMPROVEMENT OF HPV L2 PEPTIDE IMMUNOGENICITY | Deutsches Krebsforschungszentrum (DE) | 2019-04-10 | — | — | EP | disclosed |
| EP-2667892-B1 | RSV IMMUNIZATION REGIMEN | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2019-03-27 | — | — | EP | disclosed |
| EP-3442593-A1 | MACROPHAGE STIMULATION IN CD47 BLOCKADE THERAPY | Trillium Therapeutics Inc. (CA) | 2019-02-20 | — | — | EP | disclosed |
| US-20190023746-A1 | NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| CN-109195634-A | Macrophage-stimulating in CD47 blocking treatment | 延龄草疗法有限公司 | 2019-01-11 | — | — | CN | disclosed |
| US-20180280301-A1 | IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2018-10-04 | — | — | US | disclosed |
| EP-3377099-A1 | ADJUVANTING SYSTEMS AND WATER-FREE VACCINE COMPOSITIONS COMPRISING A POLYI:C POLYNUCLEOTIDE ADJUVANT AND A LIPID-BASED ADJUVANT | ImmunoVaccine Technologies Inc. (CA) | 2018-09-26 | — | — | EP | disclosed |
| US-10065994-B2 | Norovirus derived immunogenic compositions and methods | NOVARTIS AG (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180237476-A1 | PRE-FUSION RSV F ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS, SA (BE) | 2018-08-23 | — | — | US | disclosed |
| CN-108430505-A | The auxiliary system of adjuvant including polyinosinic acid polynucleotides adjuvant and based on lipid and anhydrous vaccine composition | 免疫疫苗技术有限公司 | 2018-08-21 | — | — | CN | disclosed |
| EP-3310384-A1 | VACCINE COMPOSITION | CureVac AG (DE) | 2018-04-25 | — | — | EP | disclosed |
| EP-3288538-A1 | METHODS FOR POTENTIATING AN IMMUNE RESPONSE USING DEPOT-FORMING AND NON-DEPOT-FORMING VACCINES | ImmunoVaccine Technologies Inc. (CA) | 2018-03-07 | — | — | EP | disclosed |
| CN-103189072-B | immunostimulatory method | 因纳瓦克私人有限公司 | 2018-02-09 | — | — | CN | disclosed |
| EP-3275892-A2 | PRE-FUSION RSV F ANTIGENS | GlaxoSmithKline Biologicals S.A. (BE) | 2018-01-31 | — | — | EP | disclosed |
| WO-2017211886-A1 | IMPROVEMENT OF HPV L2 PEPTIDE IMMUNOGENICITY | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2017-12-14 | — | — | WO | disclosed |
| US-9795668-B2 | Delivery of self-replicating RNA using biodegradable polymer particles | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2017-10-24 | — | — | US | disclosed |
| WO-2017177333-A1 | MACROPHAGE STIMULATION IN CD47 BLOCKADE THERAPY | TRILLIUM THERAPEUTICS INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
| EP-2707385-B1 | PRE-FUSION RSV F ANTIGENS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-09-20 | — | — | EP | disclosed |
| EP-3178490-A2 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | GlaxoSmithKline Biologicals S.A. (BE) | 2017-06-14 | — | — | EP | disclosed |
| EP-3153578-A1 | NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS | NOVARTIS AG (CH) | 2017-04-12 | — | — | EP | disclosed |
| WO-2016203025-A1 | VACCINE COMPOSITION | CUREVAC AG (DE) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016176761-A1 | METHODS FOR POTENTIATING AN IMMUNE RESPONSE USING DEPOT-FORMING AND NON-DEPOT-FORMING VACCINES | IMMUNOVACCINE TECHNOLOGIES INC., (CA) | 2016-11-10 | — | — | WO | disclosed |
| US-20160222066-A1 | NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2016-08-04 | — | — | US | disclosed |
| US-20160096905-A1 | Reduction of Endotoxin in Polysialic Acids | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2016-04-07 | — | — | US | disclosed |
| US-20160074506-A1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | NOVARTIS VACCINES AND DIAGNOSTICS INC | 2016-03-17 | — | — | US | disclosed |
| US-9212232-B2 | Reduction of endotoxin in polysialic acids | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2015-12-15 | — | — | US | disclosed |
| US-9192661-B2 | Delivery of self-replicating RNA using biodegradable polymer particles | NOVARTIS AG (CH) | 2015-11-24 | — | — | US | disclosed |
| CN-103083642-B | For the aloe preparation that skin strengthens | ALOEBIOTICS RESEARCH LABS, INC.. (US) | 2015-11-18 | — | — | CN | disclosed |
| EP-2155147-B1 | ALOE PREPARATION FOR SKIN ENHANCEMENT | WOODCLIFF SKINCARE SOLUTIONS INC (US) | 2015-10-28 | — | — | EP | disclosed |
| EP-2525815-B1 | IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES | NOVARTIS AG (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-20140248314-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2707385-A1 | PRE-FUSION RSV F ANTIGENS | Novartis AG (CH) | 2014-03-19 | — | — | EP | disclosed |
| US-20140044751-A1 | RSV IMMUNIZATION REGIMEN | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20130183355-A1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | NOVARTIS AG (CH) | 2013-07-18 | — | — | US | disclosed |
| US-20130171185-A1 | NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2013-07-04 | — | — | US | disclosed |
| US-20130172537-A1 | REDUCTION OF ENDOTOXIN IN POLYSIALIC ACIDS | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2013-07-04 | — | — | US | disclosed |
| EP-2591097-A1 | NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| EP-2591117-A1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130101609-A1 | IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| WO-2013036543-A2 | MOLECULAR IMAGING OF CANCER CELLS IN VIVO | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2012158613-A1 | PRE-FUSION RSV F ANTIGENS | NOVARTIS AG (CH) | 2012-11-22 | — | — | WO | disclosed |
| EP-2470205-A1 | ADJUVANT COMPRISING ALUMINIUM, OLIGONUCLEOTIDE AND POLYCATION | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120164176-A1 | RSV F PROTEIN COMPOSITIONS AMD METHODS FOR MAKING SAME | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2012082165-A1 | IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| EP-2453918-A2 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | Novartis AG (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-8114971-B2 | Nucleotide sequences coding gramnegative bacterial lipoprotein for use in prevention and treatment of microorganismal infection; genetic vaccine | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-02-14 | — | — | US | disclosed |
| EP-2409994-A2 | Reduction of endotoxin in polysialic acids | Lipoxen Technologies Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| EP-2409995-A2 | Reduction of endotoxin in polysialic acids | Lipoxen Technologies Limited (GB) | 2012-01-25 | — | — | EP | disclosed |
| WO-2012006293-A1 | NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006359-A1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-20110305727-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | NOVARTIS AG (CH) | 2011-12-15 | — | — | US | disclosed |
| US-20110280949-A1 | MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| EP-2115010-B1 | REDUCTION OF ENDOTOXIN IN POLYSIALIC ACIDS | LIPOXEN TECHNOLOGIES LTD (GB) | 2011-10-19 | — | — | EP | disclosed |
| US-20110250237-A1 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110159130-A1 | REDUCTION OF ENDOTOXIN IN POLYSIALIC ACIDS | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| EP-2328614-A1 | MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS | Novartis AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| EP-2313085-A2 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | Novartis AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| WO-2011024071-A1 | ADJUVANT COMPRISING ALUMINIUM, OLIGONUCLEOTIDE AND POLYCATION | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011012240-A2 | LIPOPEPTIDES FOR THERAPY AND PROPHYLAXIS OF ALLERGIC ILLNESSES | EMC MICROCOLLECTIONS GMBH (DE) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011008974-A2 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | NOVARTIS AG (CH) | 2011-01-20 | — | — | WO | disclosed |
| US-20100255130-A1 | ALOE PREPARATION FOR SKIN ENHANCEMENT | ALOEBIOTICS RESEARCH LABS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010009277-A9 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | NOVARTIS AG (CH) | 2010-03-25 | — | — | WO | disclosed |
| EP-2155147-A2 | ALOE PREPARATION FOR SKIN ENHANCEMENT | Aloebiotics Research Labs, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2010017330-A1 | MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS | NOVARTIS AG (CH) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010009277-A2 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | NOVARTIS AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100003275-A1 | Immunostimulatory Composition comprising Lipoprotein in Microalgae Extract | THE UNIVERSITY OF MISSISSIPPI (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2009137103-A2 | ANTI-CANCER/ANTI-VIRAL COMPOUNDS AND METHODS OF USE | OURTH DONALD D (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-2115010-A1 | REDUCTION OF ENDOTOXIN IN POLYSIALIC ACIDS | Lipoxen Technologies Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| EP-2064232-A2 | IMMUNOSTIMULATORY COMPOSITION COMPRISING LIPOPROTEIN IN MICROALGAE EXTRACT | University of Mississippi (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008140820-A2 | ALOE PREPARATION FOR SKIN ENHANCEMENT | ALOEBIOTICS RESEARCH LABS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-7435790-B2 | Dihydroxypropyl cysteine peptide and agent containing this peptide | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH (DE) | 2008-10-14 | — | — | US | disclosed |
| WO-2008104811-A1 | REDUCTION OF ENDOTOXIN IN POLYSIALIC ACIDS | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2008-09-04 | — | — | WO | disclosed |
| US-20080200665-A1 | Nucleic acid molecules encoding proteins which impart the adhesion of Neisseria cells to human cells | MEYER THOMAS F | 2008-08-21 | — | — | US | disclosed |
| WO-2008031092-A9 | IMMUNOSTIMULATORY COMPOSITION COMPRISING LIPOPROTEIN IN MICROALGAE EXTRACT | UNIV MISSISSIPPI (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008031092-A2 | IMMUNOSTIMULATORY COMPOSITION COMPRISING LIPOPROTEIN IN MICROALGAE EXTRACT | UNIVERSITY OF MISSISSIPPI (US) | 2008-03-13 | — | — | WO | disclosed |
| CN-1326567-C | Egg yolk antibody composition for preventing and treating atypical pneumonia and its preparation method | GUO ZHANJUN (CN) | 2007-07-18 | — | — | CN | disclosed |
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | SEIWA KASEI COMPANY, LIMITED (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1584320-A1 | COSMETIC PREPARATION CONTAINING GLYCERYLAMINO ACID DERIVATIVE | Seiwa Kasei Company, Limited (JP) | 2005-10-12 | — | — | EP | disclosed |
| US-20050192217-A1 | Utilization of lipopeptides or lipoproteins in wound treatment and infection prophylaxis | MUHLRADT PETER (DE) | 2005-09-01 | — | — | US | disclosed |
| US-20050192217-A1 | Utilization of lipopeptides or lipoproteins in wound treatment and infection prophylaxis | MUHLRADT PETER (DE) | 2005-09-01 | — | — | US | disclosed |
| US-20050124037-A1 | Nucleic acid molecules encoding proteins which impart the adhesion of Neisseria cells to human cells | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2005-06-09 | — | — | US | disclosed |
| CN-1559610-A | Vaccine curing for disease and its preparation method | 郭占军 | 2005-01-05 | — | — | CN | disclosed |
| CN-1557487-A | Immunogenicity composition for preventing and treating diseases and its preparation | 郭占军 | 2004-12-29 | — | — | CN | disclosed |
| CN-1478550-A | Egg yolk antibody composition for preventing and treating atypical pneumonia and its preparation method | 郭占军 | 2004-03-03 | — | — | CN | disclosed |
| CN-1460522-A | Egg yolk antibody composite for preventing and curing diseases and its preparaion method | GUO ZHANJUN (CN) | 2003-12-10 | — | — | CN | disclosed |
| US-20030220265-A1 | Dihydroxypropyl cysteine peptide and agent containing this peptide | MUEHLRADT PETER F (DE) | 2003-11-27 | — | — | US | disclosed |
| US-6617128-B2 | Nucleotide sequences coding proteins for use in prevention of bacteria infection; for use in treatment of gonorrhea | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2003-09-09 | — | — | US | disclosed |
| US-20030161813-A1 | Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules | LOGTENBERG TON (NL) | 2003-08-28 | — | — | US | disclosed |
| EP-1077717-B1 | USE OF LIPOPEPTIDES OR LIPOPROTEINS FOR WOUND TREATMENT | BIOTECHNOLOG FORSCHUNG GMBH (DE) | 2003-07-23 | — | — | EP | disclosed |
| US-6573242-B1 | Composition for activating macrophages comprising S-(2,3-dihydroxypropyl)-cysteine peptide having two fatty acids bonded as esters to dihydroxypropyl group and having specified amino acid sequence | GESELLSCHAFT FUER BIOTECHNOLOGISCHE (DE) | 2003-06-03 | — | — | US | disclosed |
| US-6440736-B1 | GENETIC ENGINEERING | U-BISYS B.V. (NL) | 2002-08-27 | — | — | US | disclosed |
| EP-1232184-A1 | ANTIBODY AGAINST THE HUMAN TOLL-LIKE RECEPTOR-2 (TLR2) AND USES THEREOF | Leiv Eiriksson Nyfotek AS (NO) | 2002-08-21 | — | — | EP | disclosed |
| US-20020086349-A1 | NUCLEIC ACID MOLECULES WHICH CODE PROTEINS WHICH MEDIATE THE ADHESION OF NEISSERIA CELLS TO HUMAN CELLS | MAX-PLANCK GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2002-07-04 | — | — | US | disclosed |
| WO-2001036488-A1 | ANTIBODY AGAINST THE HUMAN TOLL-LIKE RECEPTOR-2 (TLR2) AND USES THEREOF | LEIV EIRIKSSON NYFOTEK AS (NO) | 2001-05-25 | — | — | WO | disclosed |
| EP-1077717-A2 | USE OF LIPOPEPTIDES OR LIPOPROTEINS FOR WOUND TREATMENT | Gesellschaft für biotechnologische Forschung mbH (GBF) (DE) | 2001-02-28 | — | — | EP | disclosed |
| US-6074650-A | INDUCTION OF CYTOTOXIC LYMPHOCYTES | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-06-13 | — | — | US | disclosed |
| EP-1001017-A1 | Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules | U-BISys B.V. (NL) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000023570-A1 | ALTERING THE PROPERTIES OF CELLS OR OF PARTICLES WITH MEMBRANES DERIVED FROM CELLS BY MEANS OF LIPID-MODIFIED PROTEINACEOUS MOLECULES | U-BISYS B.V. (NL) | 2000-04-27 | — | — | WO | disclosed |
| US-6024964-A | ANTIBODIES AND ANTIGENS WITH MEMBRANE ANCHORING | HOECHST AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | disclosed |
| WO-1999059610-A3 | USE OF LIPOPEPTIDES OR LIPOPROTEINS FOR WOUND TREATMENT | BIOTECHNOLOG FORSCHUNG GMBH (DE) | 2000-01-20 | — | — | WO | disclosed |
| WO-1999059610-A2 | USE OF LIPOPEPTIDES OR LIPOPROTEINS FOR WOUND TREATMENT | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) (DE) | 1999-11-25 | — | — | WO | disclosed |
| WO-1995005454-A1 | ENGINEERED BACTERIOPHAGES AND VACCINES CONTAINING THEM | CAMBRIDGE BACTERIOPHAGE TECHNOLOGIES LTD. (GB) | 1995-02-23 | — | — | WO | disclosed |
| WO-1993022343-A1 | MULTIPLE ANTIGEN PEPTIDE SYSTEM HAVING ADJUVANT PROPERTIES AND VACCINES PREPARED THEREFROM | THE ROCKFELLER UNIVERSITY (US) | 1993-11-11 | — | — | WO | disclosed |
| US-4439425-A | IMMUNOLOGY | CIBA-GEIGY CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
| US-4439425-A | IMMUNOLOGY | CIBA-GEIGY CORPORATION (US) | 1984-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340645-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-10287324-B2 | Norovirus derived immunogenic compositions and methods | VSIR, CDV3, HAVCR2 | KDM4E 4256/4885MAPT 1362/4885THRB 4462/4885 |
| US-20110305727-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-20230287056-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | KDM4E 4596/4885MAPT 1260/4885THRB 4593/4885 |
| US-20140161725-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | KDM4E 4702/4885MAPT 3135/4885THRB 3353/4885 |
| US-11655284-B2 | RSV F protein compositions and methods for making same | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-20250042951-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | KDM4E 4596/4885MAPT 1260/4885THRB 4593/4885 |
| US-12139512-B2 | Pre-fusion RSV F antigens | FURIN, CD69, LY96 | KDM4E 4596/4885MAPT 1260/4885THRB 4593/4885 |
| US-11820812-B2 | RSV F protein compositions and methods for making same | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-20120164176-A1 | RSV F PROTEIN COMPOSITIONS AMD METHODS FOR MAKING SAME | MYOF, CFB, TIMCC | KDM4E 4585/4885MAPT 1389/4885THRB 3531/4885 |
| US-11261239-B2 | RSV F protein compositions and method for making same | TIMCC, RNASEL, RNGTT | KDM4E 4412/4885MAPT 1769/4885THRB 3853/4885 |
| US-20110280949-A1 | MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS | CD47, TLR9, CD74 | KDM4E 4615/4885MAPT 3698/4885THRB 3682/4885 |
| US-20060018864-A1 | Cosmetic preparation containing glycerylamino acid derivative | GLA, GPKOW, CUTA | KDM4E 3805/4885MAPT 1841/4885THRB 1305/4885 |
| US-20210230217-A1 | OPTIMISED COMPOUNDS | TLR2, TLR3, TLR1 | KDM4E 4387/4885MAPT 3811/4885THRB 905/4885 |
| US-20220332767-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | KDM4E 4596/4885MAPT 1260/4885THRB 4593/4885 |
| US-20230348574-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-11458212-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | KDM4E 4702/4885MAPT 3135/4885THRB 3353/4885 |
| US-11629181-B2 | RSV F protein compositions and methods for making same | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-11813323-B2 | RSV immunization regimen | IL5, IL15, IFNG | KDM4E 4652/4885MAPT 2978/4885THRB 4399/4885 |
| US-20240299527-A1 | RSV IMMUNIZATION REGIMEN | IL5, IL15, IFNG | KDM4E 4652/4885MAPT 2978/4885THRB 4399/4885 |
| US-20230357371-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-20230357369-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-10065994-B2 | Norovirus derived immunogenic compositions and methods | VSIR, CDV3, HAVCR2 | KDM4E 4256/4885MAPT 1362/4885THRB 4462/4885 |
| US-20050192217-A1 | Utilization of lipopeptides or lipoproteins in wound treatment and infection prophylaxis | LNPEP, CUTA, LIPA | KDM4E 4776/4885MAPT 4820/4885THRB 2434/4885 |
| US-10485761-B2 | Irradiated biodegradable polymer microparticles | EXOSC9, TNF, EXOSC5 | KDM4E 2607/4885MAPT 3797/4885THRB 4679/4885 |
| US-10406248-B2 | Molecular imaging of cancer cells in vivo | MKI67, ANXA4, ANXA3 | KDM4E 4702/4885MAPT 3135/4885THRB 3353/4885 |
| US-20160074506-A1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | RNGTT, POLRMT, POLR2H | KDM4E 3655/4885MAPT 2380/4885THRB 4465/4885 |
| US-20220372115-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-20250066416-A1 | OPTIMISED COMPOUNDS | TLR2, TLR3, TLR1 | KDM4E 4387/4885MAPT 3811/4885THRB 905/4885 |
| US-20240239845-A1 | PRE-FUSION RSV F ANTIGENS | FURIN, CD69, LY96 | KDM4E 4596/4885MAPT 1260/4885THRB 4593/4885 |
| US-12195557-B2 | Optimised compounds | TLR2, TLR3, TLR1 | KDM4E 4387/4885MAPT 3811/4885THRB 905/4885 |
| US-20190023746-A1 | NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS | VSIR, CDV3, HAVCR2 | KDM4E 4265/4885MAPT 1482/4885THRB 4455/4885 |
| US-20130183355-A1 | DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES | RNGTT, POLRMT, POLR2H | KDM4E 3655/4885MAPT 2380/4885THRB 4465/4885 |
| US-20110250237-A1 | IMMUNOGENIC AMPHIPATHIC PEPTIDE COMPOSITIONS | TAP1, TAP2, MICA | KDM4E 4849/4885MAPT 2277/4885THRB 3362/4885 |
| US-11452773-B2 | RSV immunization regimen | IL5, IL15, IFNG | KDM4E 4652/4885MAPT 2978/4885THRB 4399/4885 |
| US-20230072995-A1 | RSV IMMUNIZATION REGIMEN | IL5, IL15, IFNG | KDM4E 4652/4885MAPT 2978/4885THRB 4399/4885 |
| US-20230303669-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-20200164093-A1 | Molecular Imaging of Cancer Cells In Vivo | MKI67, ANXA4, ANXA3 | KDM4E 4702/4885MAPT 3135/4885THRB 3353/4885 |
| US-20180280301-A1 | IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES | EXOSC9, TNF, EXOSC5 | KDM4E 2607/4885MAPT 3797/4885THRB 4679/4885 |
| US-20130171185-A1 | NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS | VSIR, CDV3, HAVCR2 | KDM4E 4256/4885MAPT 1362/4885THRB 4462/4885 |
| US-20220213177-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-10342862-B2 | RSV immunization regimen | IL5, IL15, IFNG | KDM4E 4652/4885MAPT 2978/4885THRB 4399/4885 |
| US-20130101609-A1 | IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES | EXOSC9, TNF, EXOSC5 | KDM4E 2607/4885MAPT 3797/4885THRB 4679/4885 |
| US-20200172600-A1 | RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME | TIMCC, RNASEL, RNGTT | KDM4E 4412/4885MAPT 1769/4885THRB 3853/4885 |
| US-20190275141-A1 | RSV IMMUNIZATION REGIMEN | IL5, IL15, IFNG | KDM4E 4652/4885MAPT 2978/4885THRB 4399/4885 |
| US-11827694-B2 | RSV F protein compositions and methods for making same | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-20160222066-A1 | NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS | VSIR, CDV3, HAVCR2 | KDM4E 4265/4885MAPT 1482/4885THRB 4455/4885 |
| US-20240034773-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-20230357370-A1 | RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME | RNASEL, TIMCC, RNGTT | KDM4E 4397/4885MAPT 1801/4885THRB 3887/4885 |
| US-20140044751-A1 | RSV IMMUNIZATION REGIMEN | IL5, IL15, IFNG | KDM4E 4652/4885MAPT 2978/4885THRB 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.